1764-1765 / 2437
• Approved for the treatment of CMV retinitis in HIV-positive
patients or for prophylaxis in immunocompromised subjects
• Side effects: nausea, diarrhea, headache,
myelosuppression, fetal toxicity…
• Metabolized to ganciclovir by a CMV-encoded thymidine
kinase
concentrates in CMV-infected cells
• Inhibitor of dGTP: incorporated into viral DNA
inhibits viral
DNA polymerases which results in chain termination
Valganciclovir